Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-01-29

FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA supplemental application submitted for Alecensa (alectinib hydrochloride) by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)